EASL Campus

A 57-year-old man with alcohol-related compensated cirrhosis, smoker, with compensated diabetes. He performed a CE-TC scan following an abdominal US detection of 3 focal liver lesions. The CT scan showed 7 lesions from 10 mm to 55 mm with peripheral enhancement, partial invasion of left portal branch and left lobe biliary ducts dilatation: radiological features suspected for locally advanced iCCA. He is asymptomatic in good general condition, (ECOG PS 0), blood tests showed a serum bilirubin of 1.8 mg/dL, increased ALP and GGT (4x), AFP normal value, Ca 19.9 3x.

Should systemic therapy be considered for the first-line option in this patient with locally advanced, unresectable intrahepatic cholangiocarcinoma (iCCA) with a good performance status?

A. Chemotherapy with gemcitabine plus cisplatin should be considered the first line systemic treatment, considering durvalumab only in second line

B. Chemotherapy with gemcitabine plus cisplatin should be considered the first line systemic treatment, considering durvalumab where available

C. Locoregional treatment should be always considered instead of systemic chemotherapy for iCCA

D. Durvalumab is the treatment of choice for first line therapy in unresectable iCCA

Community Stream

Easl Community Feed My Feed